187 related articles for article (PubMed ID: 30105657)
21. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
22. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study.
Ji Y; Song Y; Zhou F; Liu T; Jiang M; Zhao X; Huang X
Medicine (Baltimore); 2017 Dec; 96(52):e9443. PubMed ID: 29384927
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
25. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis.
Wingen-Heimann SM; Cornely OA; Vehreschild MJGT; Wisplinghoff H; Franke B; Schons M; von Bergwelt-Baildon M; Scheid C; Vehreschild JJ
Mycoses; 2021 Apr; 64(4):437-444. PubMed ID: 33354800
[TBL] [Abstract][Full Text] [Related]
27. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
28. Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom.
Earnshaw SR; McDade C; Bryan A; Ines M; Micallef C; Sung A; Enoch DA
Microbiol Spectr; 2022 Jun; 10(3):e0042522. PubMed ID: 35532266
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection.
Hashii Y; Kusuki S; Takizawa S; Tokimasa S; Ohta H; Hara J; Ozono K
Pediatr Int; 2014 Dec; 56(6):834-837. PubMed ID: 24730676
[TBL] [Abstract][Full Text] [Related]
30. Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.
Baker AW; Maziarz EK; Arnold CJ; Johnson MD; Workman AD; Reynolds JM; Perfect JR; Alexander BD
Clin Infect Dis; 2020 Jan; 70(1):30-39. PubMed ID: 30801642
[TBL] [Abstract][Full Text] [Related]
31. Micafungin use in children.
Emiroglu M
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789
[TBL] [Abstract][Full Text] [Related]
32. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
33. Breakthrough Candidemia In Children On Micafungin.
Funaki T; Miyairi I
Pediatr Infect Dis J; 2018 Dec; 37(12):1258-1260. PubMed ID: 29570179
[TBL] [Abstract][Full Text] [Related]
34. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
Kusuki S; Hashii Y; Yoshida H; Takizawa S; Sato E; Tokimasa S; Ohta H; Ozono K
Pediatr Blood Cancer; 2009 Oct; 53(4):605-9. PubMed ID: 19533659
[TBL] [Abstract][Full Text] [Related]
35. [Results of the use of micafungin in newborns].
Çakır SÇ; Çelebi S; Özkan H; Köksal N; Dorum BA; Yeşil E; Hacımustafaoğlu M
Mikrobiyol Bul; 2019 Jan; 53(1):70-80. PubMed ID: 30683041
[TBL] [Abstract][Full Text] [Related]
36. Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.
Villaescusa T; Vázquez L; Bergua JM; García J; Romero A; Olave MT; García Belmonte D; Queipo de Llano MP;
Rev Esp Quimioter; 2020 Feb; 33(1):44-48. PubMed ID: 31865649
[TBL] [Abstract][Full Text] [Related]
37. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
[TBL] [Abstract][Full Text] [Related]
38. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
Nachbaur D; Angelova O; Orth-Höller D; Ditlbacher A; Lackner M; Auberger J; Lass-Flörl C
Eur J Haematol; 2015 Mar; 94(3):258-64. PubMed ID: 25082655
[TBL] [Abstract][Full Text] [Related]
39. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
[TBL] [Abstract][Full Text] [Related]
40. Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice.
Chandwani S; Wentworth C; Burke TA; Patterson TF
Curr Med Res Opin; 2009 Feb; 25(2):385-93. PubMed ID: 19192983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
